INVERSAGO-PHARMA
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma Conference being held January 31 through February 2, 2023.
For additional information or to request a meeting with management, please contact conference representatives.
About Inversago Pharma
Inversago Pharma is a privately owned, clinical stage, Canadian biotech company, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic kidney disease (DKD), including diabetic nephropathy (DN), type 1 and type 2 diabetes (T1D / T2D), non-alcoholic steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like progressive fibrosis-interstitial lung disease (PF-ILD), including idiopathic pulmonary fibrosis (IPF) and other conditions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005328/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis24.11.2025 14:00:00 CET | Press release
Cladribine capsules have the potential to be the first oral treatment for people living with rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia GravisCladribine capsules has received Fast Track designation and Orphan Drug Designation by the US FDAMerck has established an MG patient council to provide insights on how to best meet the needs of patients in the gMG rare disease community Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for cladribine capsules for the treatment of the rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia Gravis (gMG). In June 2023, the FDA granted Orphan Drug Designation for cladribine capsules for the treatment of gMG. In addition, the Company is actively collaborating with patient organizations and Ad Scientiam, a medical technology company, to support a patient-directed approach to the future management of gMG. If approved
BENEFIT and Ant International Partner to Launch Alipay+ in Bahrain to Achieve Global E-Wallet Connectivity24.11.2025 13:04:00 CET | Press release
Partnership will integrate Alipay+ with BENEFIT, Bahrain’s national QR payment scheme, to enable all Bahraini merchants to accept cross-border digital payments from leading digital wallets and explore outbound payment capabilities. Both parties will explore developing next-generation digital payment framework to support Bahrain’s digital transformation journey. BENEFIT, the Bahraini innovator and a leading company in fintech and electronic financial transactions service, and Ant International, a leading global digital payment, digitisation and financial technology provider, headquartered in Singapore, have partnered to launch cross-border QR payments between Bahrain’s BENEFIT QR payment scheme and Ant International’s global wallet gateway, Alipay+, during 2026 to support the transition toward a more inclusive digital payments ecosystem. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124405672/en/ (L-R): Hessa Husain, Depu
NIQ Joins TikTok Marketing Partners Program Earning Media Mix Modeling Badge24.11.2025 12:00:00 CET | Press release
Recognition underscores NIQ’s leadership in delivering advanced analytics and full-funnel outcomes measurement on TikTok. NIQ, a global leader in consumer intelligence, has earned a partner badge in TikTok’s newly launched Media Mix Modeling (MMM) program – a focus area within TikTok’s Marketing Partners Program. The Marketing Partners Program is composed of carefully selected third-party partners across different categories and specialties who have met TikTok’s rigorous standards for quality and expertise. Badging signals advanced proficiency in media analytics, ensuring state-of-the-art MMM measurement for marketers around the world. As a badged MMM Marketing Partner, NIQ can help advertisers measure the full funnel impact of their marketing campaigns on TikTok and TikTok Shop, enabling them to optimize strategies based on data-driven insights that look beyond last click attribution. As part of the Marketing Partners Program, TikTok’s new reporting API is integrated into NIQ, providi
LRN Sponsors 2025 Nordic Ethics & Compliance Survey to Advance Region-Specific Insights on Responsible Business Conduct24.11.2025 10:00:00 CET | Press release
LRN and Nordic Business Ethics partner to elevate region-specific insights that strengthen global E&C effectiveness LRN Corporation, a leader in ethics and compliance (E&C) solutions, announced its sponsorship of the 2025 Nordic Ethics & Compliance Survey, an annual study by Nordic Business Ethics examining how organizations across the Nordic region integrate ethics, responsibility, and compliance into daily decision-making. LRN’s sponsorship supports the survey’s mission to highlight regional insights that enrich global understanding of workplace ethics. The partnership reflects LRN’s belief that effective E&C programs are not a one-size-fits-all solution and must be informed by regional cultural norms and organizational identity. The survey data shows that while Nordic organizations excel in values-driven ethics, their experience mirrors a global trend of increased regulatory expectations and company growth straining operational systems and governance structures. “Nordic organization
IonQ Appoints Dr. Marco Pistoia as CEO of IonQ Italia to Spearhead Strategic Quantum Initiatives Across the Country24.11.2025 09:00:00 CET | Press release
Industry veteran Pistoia to drive enterprise and research engagement as IonQ deepens investment in Italy’s quantum future IonQ (NYSE: IONQ), the world’s leading quantum company, today announced the appointment of Dr. Marco Pistoia, Ph.D., as Chief Executive Officer of IonQ Italia S.r.l., a wholly owned subsidiary. Dr. Pistoia will lead IonQ’s strategic initiatives in Italy, building on the company’s momentum as the world’s only full-stack quantum platform provider across quantum computing, quantum networking, quantum sensing, and quantum security. IonQ Italia will help establish Italy as a dynamic powerhouse in the global quantum landscape. Dr. Pistoia and his team will focus on expanding access to IonQ’s advanced quantum systems for Italian enterprises, research institutions, and government partners. The team will be tasked with driving innovation in quantum applications for key sectors such as finance, energy, aerospace, defense, pharmaceuticals, and advanced manufacturing. “Italy is
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom